BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 Nazeer B, Khawar MB, Khalid MU, Hamid SE, Rafiq M, Abbasi MH, Sheikh N, Ali A, Fatima H, Ahmad S. Emerging role of lipophagy in liver disorders. Mol Cell Biochem 2023. [PMID: 36943663 DOI: 10.1007/s11010-023-04707-1] [Reference Citation Analysis]
2 Song C, Long X, He J, Huang Y. Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1081334] [Reference Citation Analysis]
3 Meringer H, Wang A, Mehandru S. The Pathogenesis of Gastrointestinal, Hepatic, and Pancreatic Injury in Acute and Long Coronavirus Disease 2019 Infection. Gastroenterol Clin North Am 2023;52:1-11. [PMID: 36813418 DOI: 10.1016/j.gtc.2022.12.001] [Reference Citation Analysis]
4 Xue X, Wang J, Fu K, Dai S, Wu R, Peng C, Li Y. The role of miR-155 on liver diseases by modulating immunity, inflammation and tumorigenesis. Int Immunopharmacol 2023;116:109775. [PMID: 36753984 DOI: 10.1016/j.intimp.2023.109775] [Reference Citation Analysis]
5 Gulzar F, Ahmad S, Singh S, Kumar P, Sharma A, Tamrakar AK. NOD1 activation in 3T3-L1 adipocytes confers lipid accumulation in HepG2 cells. Life Sci 2023;316:121400. [PMID: 36657640 DOI: 10.1016/j.lfs.2023.121400] [Reference Citation Analysis]
6 Ye M, Fan S, Li X, Yang S, Ji C, Ji F, Zhou B. Four flavonoids from propolis ameliorate free fatty acids-induced non-alcoholic steatohepatitis in HepG2 cells: Involvement of enhanced AMPK activation, mTOR-NF-κBp65 interaction, and PTEN expression. Journal of Functional Foods 2023;102:105460. [DOI: 10.1016/j.jff.2023.105460] [Reference Citation Analysis]
7 Morrison MA, Artru F, Trovato FM, Triantafyllou E, McPhail MJ. Potential therapies for acute-on-chronic liver failure. Liver Int 2023. [PMID: 36800487 DOI: 10.1111/liv.15545] [Reference Citation Analysis]
8 Kohlhepp MS, Liu H, Tacke F, Guillot A. The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-Challenges and opportunities. Front Mol Biosci 2023;10:1129831. [PMID: 36845555 DOI: 10.3389/fmolb.2023.1129831] [Reference Citation Analysis]
9 Kelty TJ, Dashek RJ, Arnold WD, Rector RS. Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration. Semin Liver Dis 2023;43:77-88. [PMID: 36764305 DOI: 10.1055/s-0043-1762585] [Reference Citation Analysis]
10 Munkong N, Somnuk S, Jantarach N, Ruxsanawet K, Nuntaboon P, Kanjoo V, Yoysungnoen B. Red Rice Bran Extract Alleviates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease and Dyslipidemia in Mice. Nutrients 2023;15. [PMID: 36615905 DOI: 10.3390/nu15010246] [Reference Citation Analysis]
11 Hadjihambi A, Konstantinou C, Klohs J, Monsorno K, Le Guennec A, Donnelly C, Cox IJ, Kusumbe A, Hosford PS, Soffientini U, Lecca S, Mameli M, Jalan R, Paolicelli RC, Pellerin L. Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction. J Hepatol 2023;78:180-90. [PMID: 35995127 DOI: 10.1016/j.jhep.2022.08.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
12 He W, Huang C, Shi X, Wu M, Li H, Liu Q, Zhang X, Zhao Y, Li X. Single-cell transcriptomics of hepatic stellate cells uncover crucial pathways and key regulators involved in non-alcoholic steatohepatitis. Endocr Connect 2023;12. [PMID: 36562664 DOI: 10.1530/EC-22-0502] [Reference Citation Analysis]
13 Altamimy KM, Alshammari GM, Yagoub AEA, Albekairi NA, Alshehri S, Saleh A, Yahya MA. Saudi Traditional Fermented Goat Milk Protects against Experimental Non-Alcoholic Fatty Liver Disease by Hypoglycaemic and Antioxidant Potentials. Fermentation 2022;8:735. [DOI: 10.3390/fermentation8120735] [Reference Citation Analysis]
14 Alharthi J, Bayoumi A, Thabet K, Pan Z, Gloss BS, Latchoumanin O, Lundberg M, Twine NA, McLeod D, Alenizi S, Adams LA, Weltman M, Berg T, Liddle C, George J, Eslam M. A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nat Commun 2022;13:7430. [PMID: 36473860 DOI: 10.1038/s41467-022-35158-9] [Reference Citation Analysis]
15 Sinn DH, Kang D, Kang M, Guallar E, Hong YS, Lee KH, Park J, Cho J, Gwak GY. Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study. Hepatology 2022;76:1746-54. [PMID: 35588190 DOI: 10.1002/hep.32578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
16 Wang JS, Liu JC. Intestinal microbiota in the treatment of metabolically associated fatty liver disease. World J Clin Cases 2022; 10(31): 11240-11251 [DOI: 10.12998/wjcc.v10.i31.11240] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Martinez-Sanchez N, Sweeney O, Sidarta-Oliveira D, Caron A, Stanley SA, Domingos AI. The sympathetic nervous system in the 21st century: Neuroimmune interactions in metabolic homeostasis and obesity. Neuron 2022;110:3597-626. [PMID: 36327900 DOI: 10.1016/j.neuron.2022.10.017] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Harkus U, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Semin Cancer Biol 2022;86:799-815. [PMID: 35065242 DOI: 10.1016/j.semcancer.2022.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
19 Vyletelová V, Nováková M, Pašková Ľ. Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals 2022;15:1278. [DOI: 10.3390/ph15101278] [Reference Citation Analysis]
20 Ortiz-lópez N, Fuenzalida C, Dufeu MS, Pinto-león A, Escobar A, Poniachik J, Roblero JP, Valenzuela-pérez L, Beltrán CJ. The immune response as a therapeutic target in non-alcoholic fatty liver disease. Front Immunol 2022;13:954869. [DOI: 10.3389/fimmu.2022.954869] [Reference Citation Analysis]
21 Guo Z, Fan X, Yao J, Tomlinson S, Yuan G, He S. The role of complement in nonalcoholic fatty liver disease. Front Immunol 2022;13:1017467. [DOI: 10.3389/fimmu.2022.1017467] [Reference Citation Analysis]
22 Sitthirach C, Charoensuk L, Pairojkul C, Chaidee A, Intuyod K, Pongking T, Thongpon P, Jantawong C, Hongsrichan N, Waraasawapati S, Yingklang M, Pinlaor S. Curcumin-loaded nanocomplexes ameliorate the severity of nonalcoholic steatohepatitis in hamsters infected with Opisthorchis viverrini. PLoS ONE 2022;17:e0275273. [DOI: 10.1371/journal.pone.0275273] [Reference Citation Analysis]
23 Wupperfeld D, Fricker G, Bois De Fer B, Frank L, Wehrle A, Popovic B. Essential phospholipids decrease apoptosis and increase membrane transport in human hepatocyte cell lines. Lipids Health Dis 2022;21. [DOI: 10.1186/s12944-022-01698-8] [Reference Citation Analysis]
24 Yahya MA, Alshammari GM, Osman MA, Al-Harbi LN, Yagoub AEA, AlSedairy SA. Liquorice root extract and isoliquiritigenin attenuate high-fat diet-induced hepatic steatosis and damage in rats by regulating AMPK. Arch Physiol Biochem 2022;:1-16. [PMID: 36121371 DOI: 10.1080/13813455.2022.2102654] [Reference Citation Analysis]
25 Tao W, Jin F, Fan Q, Zhao N, Wang G, Du E, Chen F, Guo W, Huang S, Chen M, Wei J. Effects of Chitosan Oligosaccharide on Production Performance, Egg Quality and Ovarian Function in Laying Hens with Fatty Liver Syndrome. Animals 2022;12:2465. [DOI: 10.3390/ani12182465] [Reference Citation Analysis]
26 Heredia JE, Sorenson C, Flanagan S, Nunez V, Jones C, Martzall A, Leong L, Martinez AP, Scherl A, Brightbill HD, Ghilardi N, Ding N. IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models. PLoS ONE 2022;17:e0274582. [DOI: 10.1371/journal.pone.0274582] [Reference Citation Analysis]
27 Choi SE, Hwang Y, Lee SJ, Jung H, Shin TH, Son Y, Park S, Han SJ, Kim HJ, Lee KW, Lee G, Kemper JK, Song HK, Kang Y. Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice. J Hepatol 2022;77:735-47. [PMID: 35421426 DOI: 10.1016/j.jhep.2022.03.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Zhang S, Lu S, Li Z. Extrahepatic factors in hepatic immune regulation. Front Immunol 2022;13:941721. [DOI: 10.3389/fimmu.2022.941721] [Reference Citation Analysis]
29 Xiao J, Li X, Zhou Z, Guan S, Zhuo L, Gao B. Development of an in vitro insulin resistance dissociated model of hepatic steatosis by co-culture system. Biosci Trends 2022. [PMID: 35965099 DOI: 10.5582/bst.2022.01242] [Reference Citation Analysis]
30 Lu X, Yang Y, Lu Y. Immunosenescence: A Critical Factor Associated With Organ Injury After Sepsis. Front Immunol 2022;13:917293. [DOI: 10.3389/fimmu.2022.917293] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yan M, Man S, Ma L, Gao W. Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. Metabolism 2022;134:155264. [PMID: 35810782 DOI: 10.1016/j.metabol.2022.155264] [Reference Citation Analysis]
32 Liu D, Yuan X, Gao F, Zhao B, Ding L, Huan M, Liu C, Jiang L. High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients. Front Immunol 2022;13:899930. [DOI: 10.3389/fimmu.2022.899930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Møhlenberg M, Eriksen PL, Laursen TL, Nielsen MB, Hamilton Dutoit SJ, Grønbæk H, Hartmann R, Thomsen KL. The presence of interferon affects the progression of non-alcoholic fatty liver disease. Genes Immun 2022. [PMID: 35725929 DOI: 10.1038/s41435-022-00176-6] [Reference Citation Analysis]
34 Miao L, Targher G, Byrne CD, Valenti L, Qi X, Zheng M. Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives. Portal Hypertension & Cirrhosis 2022;1:57-65. [DOI: 10.1002/poh2.8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Gupta B, Rai R, Oertel M, Raeman R. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. Semin Liver Dis 2022;42:122-37. [PMID: 35738255 DOI: 10.1055/s-0042-1748037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Alzahrani NS, Alshammari GM, El-Ansary A, Yagoub AEA, Amina M, Saleh A, Yahya MA. Anti-Hyperlipidemia, Hypoglycemic, and Hepatoprotective Impacts of Pearl Millet (Pennisetum glaucum L.) Grains and Their Ethanol Extract on Rats Fed a High-Fat Diet. Nutrients 2022;14:1791. [PMID: 35565759 DOI: 10.3390/nu14091791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Mohammed HM. Zingerone ameliorates non-alcoholic fatty liver disease in rats by activating AMPK. J Food Biochem 2022;:e14149. [PMID: 35338494 DOI: 10.1111/jfbc.14149] [Reference Citation Analysis]
38 Wei W, Xu R, Ying X, Chen L, Lu X, Tang Q, Xie J, Yu H. Transcriptome Analysis of Solute Carrier-Associated Genes in Hepatocellular Carcinoma: Friend or Foe? Front Genet 2022;13:856393. [DOI: 10.3389/fgene.2022.856393] [Reference Citation Analysis]
39 Nakamoto K, Tokuyama S. Docosahexaenoic Acid Attenuates the Progression of Nonalcoholic Steatohepatitis by Suppressing the Adipocyte Inflammation via the G Protein-Coupled Receptor 120/Free Fatty Acid Receptor 4 Pathway. Pharmacology 2022;:1-9. [PMID: 35189618 DOI: 10.1159/000522117] [Reference Citation Analysis]
40 Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol 2022;19:177-91. [PMID: 35039631 DOI: 10.1038/s41423-021-00832-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 21.0] [Reference Citation Analysis]
41 Prikhodko VA, Bezborodkina NN, Okovityi SV. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022;10:274. [DOI: 10.3390/biomedicines10020274] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
42 Tripodi A, Lombardi R, Primignani M, La Mura V, Peyvandi F, Fracanzani AL. Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines 2022;10:249. [PMID: 35203457 DOI: 10.3390/biomedicines10020249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 Almohawes ZN, El-kott A, Morsy K, Shati AA, El-kenawy AE, Khalifa HS, Elsaid FG, Abd-lateif AM, Abu-zaiton A, Ebealy ER, Abdel-daim MM, Ghanem RA, Abd-ella EM. Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and muscles of high fat diet-fed rats. Archives of Physiology and Biochemistry. [DOI: 10.1080/13813455.2021.2024578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
44 Forlano R, Mullish BH, Roberts LA, Thursz MR, Manousou P. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:662. [PMID: 35054847 DOI: 10.3390/ijms23020662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
45 Spremović Rađenović S, Pupovac M, Andjić M, Bila J, Srećković S, Gudović A, Dragaš B, Radunović N. Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). Biomedicines 2022;10:131. [DOI: 10.3390/biomedicines10010131] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
46 Sommer A, Ade K, Freyer L, Gomez Perdiguero E. Development and Function of Macrophages. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00259-5] [Reference Citation Analysis]
47 Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. Front Med (Lausanne) 2021;8:781567. [PMID: 34957156 DOI: 10.3389/fmed.2021.781567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Wang JH, Hwang SJ, Lim DW, Son CG. Cynanchum atratum Alleviates Non-Alcoholic Fatty Liver by Balancing Lipogenesis and Fatty Acid Oxidation in a High-Fat, High-Fructose Diet Mice Model. Cells 2021;11:23. [PMID: 35011585 DOI: 10.3390/cells11010023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol 2021;12:667354. [PMID: 34899679 DOI: 10.3389/fimmu.2021.667354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Le Garf S, Nègre V, Anty R, Gual P. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem. Biomedicines 2021;9:1915. [PMID: 34944730 DOI: 10.3390/biomedicines9121915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
52 Swift O, Sharma S, Ramanarayanan S, Umar H, Laws KR, Vilar E, Farrington K. Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis. Clinical Kidney Journal 2021. [DOI: 10.1093/ckj/sfab230] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Jeyakumar SM, Vajreswari A. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World J Clin Cases 2021; 9(31): 9333-9349 [PMID: 34877270 DOI: 10.12998/wjcc.v9.i31.9333] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Zhang J, Kang X, Zhang L, Wang H, Deng Z. Identification of a 17-gene-signature in Non-alcoholic Steatohepatitis and Its Relationship with Immune Cell Infiltration. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.116366] [Reference Citation Analysis]
55 Zenlander R, Havervall S, Magnusson M, Engstrand J, Ågren A, Thålin C, Stål P. Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma. Sci Rep 2021;11:18025. [PMID: 34504150 DOI: 10.1038/s41598-021-97233-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
56 Luci C, Vieira E, Bourinet M, Rousseau D, Bonnafous S, Patouraux S, Lefevre L, Larbret F, Prod'homme V, Iannelli A, Tran A, Anty R, Bailly-Maitre B, Deckert M, Gual P. SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2022;13:173-91. [PMID: 34411785 DOI: 10.1016/j.jcmgh.2021.08.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Berdja S, Boudarene L, Smail L, Neggazi S, Boumaza S, Sahraoui A, Haffaf EM, Kacimi G, Aouichat Bouguerra S. Scolymus hispanicus (Golden Thistle) Ameliorates Hepatic Steatosis and Metabolic Syndrome by Reducing Lipid Accumulation, Oxidative Stress, and Inflammation in Rats under Hyperfatty Diet. Evid Based Complement Alternat Med 2021;2021:5588382. [PMID: 34335826 DOI: 10.1155/2021/5588382] [Reference Citation Analysis]
58 Zhang L, Li HL, Zhang DD, Cui XC. Therapeutic effects of myocardin-related transcription factor A (MRTF-A) knockout on experimental mice with nonalcoholic steatohepatitis induced by high-fat diet. Hum Exp Toxicol 2021;:9603271211002886. [PMID: 33779332 DOI: 10.1177/09603271211002886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]